Company intelligence / Profile preview

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu, Sichuan Province, Chinaen.cnkh.com ↗

Ownership: Private
Employees: ~4000
Development stage: Commercial

Overview

The company has 18 drugs on the market including Lumitin (conbercept) for AMD. Their Phase 3 PANDA-1 trial for conbercept in neovascular AMD was stopped in 2021 due to difficulties caused by global health emergencies. Recently, their dual-payload ADC KH815 entered Phase 1 clinical trials for solid tumors in April 2025.

Therapeutic areas: OncologyEndocrinologyGastroenterologyOphthalmologyNeurology
Modalities: ProteinsAntibody-Drug Conjugates (ADCs)Small molecules
Industry: Biotech

Drug pipeline

26 assets

conbercept

25 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chengdu Kanghong Pharmaceutical Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Kanghong Pharmaceutical Group Co., Ltd..

Explore the full profile